Remestemcel-L Clinical and Potency Studies Presented at
NEW YORK, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory...
Source: globenewswire.com
Page 4 - Steve Dabkowski News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Steve Dabkowski. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Steve Dabkowski Today - Breaking & Trending Today
Mesoblast Resubmits Biologic License Application (BLA) to
Validation of Remestemcel-L Potency Assay used in the Phase 3 Trial which Measures In-Vivo Activity based on Mechanism of Action Assay Identifies...
Source: globenewswire.com
Children Treated With Remestemcel-L Show Long-Term Survival
Key Points: Long-term survival evident through 4 years in children treated with remestemcel-L in Phase 3 trial MSB-GVHD001Overall survival at 2 years...
Source: globenewswire.com
Mesoblast Reports Financial Results and Operational Highlights for the Period Ended September 30, 2022
23.11.2022 - Durable long-term survival outcomes through 4 years for children with steroid-refractory graft versus host disease (SR-aGVHD) treated with remestemcel-L These long-term survival outcomes are a cornerstone of the BLA resubmission to FDA for ...
Source: wallstreet-online.de
Mesoblast Operational and Financial Highlights for Quarter
Quarterly Activity Report...
Source: globenewswire.com